PT - JOURNAL ARTICLE AU - Kim Sneppen AU - Lone Simonsen TI - Impact of Superspreaders on dissemination and mitigation of COVID-19 AID - 10.1101/2020.05.17.20104745 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.17.20104745 4099 - http://medrxiv.org/content/early/2020/05/31/2020.05.17.20104745.short 4100 - http://medrxiv.org/content/early/2020/05/31/2020.05.17.20104745.full AB - Background The severity of the Covid-19 pandemic has led to the use of extreme control measures which has halted the spread, but at enormous socioeconomic cost. We set out to explore whether a model that includes ‘superspreader’ could explain aspects of mitigation strategies that explain the dramatic effect.Methods We developed an age structured agent-based model that includes persons who spread the disease far more widely than others, acting in a society in which transmission occurs in three sectors: home, school/work and a third category representing other social contacts. We employ the model to study the impact of lock-down when superspreaders are present.Findings As expected, without mitigation imposed, the inclusion of superspreaders in the population does not change the epidemic trajectory. However in a structured society we find that superspreaders made a substantial difference. Our simulations demonstrate that workplaces and schools may open without much effect on the epidemic, as long as the other social contacts are drastically limited.Interpretation The recent observations of profound pandemic control that cannot be captured by standard SEIR models, require disease transmission models that consider superspreaders. We have found that transmission can be controlled simply by limiting contacts such as public transportation and large events. Indeed, eliminating superspreader opportunities can uniquely explain the observed control of the epidemic with Sweden’s relaxed approach and with the moderate lock-down used in Denmark.Funding KS received funding from the EU Horizon 2020 research program under ERC grant No. 740704, and LS from the Carlsberg Foundation in Denmark.Research in context:Evidence before this study:Since the emergence of SARS-CoV-2 in China, superspreaders are emerging as a theme, as it was also the case with SARS-CoV in 2003. Analyzing COVID-19 data, substantial individual-level variation in transmissibility has been inferred, and it has been estimated that 10% of infected persons cause 80% of all infections.Added value of this study:We developed an agent-based socially structured model to simulate the effect of superspreaders on the epidemic, and in the context of country lockdowns and reopenings. Our simulations demonstrate that COVID-19 is effectively mitigated if one limits social activity where many strangers meet, as superspreaders will infect mainly among the many people they rarely meet.Implications of all available evidence:Modelling heterogeneity and super spreading is critical in terms of understanding observed COVID-19 epidemic patterns. Indeed, mitigating superspreading opportunities is an effective way to mitigate Covid-19 and prevent second waves because the remaining population cannot sustain the epidemic. The superspreader phenomenon may also explain the observation of huge COVID-19 epidemic variability between different areas in the same country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement No. 740704, and from the Carlsberg Foundation in Denmark.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB body involved here. It is a theoretical paper using publically available data from Danish, Norwegian and Swedish health authorities.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data.